CYCC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CYCC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
For the three months ended in Dec. 2023, Cyclacel Pharmaceuticals spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Cyclacel Pharmaceuticals gained $0.00 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2023.
The historical data trend for Cyclacel Pharmaceuticals's Cash Flow from Investing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyclacel Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Cash Flow from Investing | Get a 7-Day Free Trial | 0.03 | -0.10 | -0.03 | -0.01 | -0.01 |
Cyclacel Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cash Flow from Investing | Get a 7-Day Free Trial | - | -0.01 | - | - | - |
Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).
Likewise, if a company buys another company for cash, this will reduce their cash position.
Cyclacel Pharmaceuticals's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:
Cyclacel Pharmaceuticals's Cash Flow from Investing for the quarter that ended in Dec. 2023 is calculated as:
Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyclacel Pharmaceuticals (NAS:CYCC) Cash Flow from Investing Explanation
Cash flow from investing contains nine items:
1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.
Cyclacel Pharmaceuticals's purchase of property, plant, equipment for the three months ended in Dec. 2023 was $0.00 Mil. It means Cyclacel Pharmaceuticals spent $0.00 Mil on purchasing property, plant, equipment.
In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.
In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.
Cyclacel Pharmaceuticals's sale of property, plant, equipment for the three months ended in Dec. 2023 was $0.00 Mil. It means Cyclacel Pharmaceuticals gained $0.00 Mil from selling property, plant, and equipment.
3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.
Cyclacel Pharmaceuticals's purchase of business for the three months ended in Dec. 2023 was $0.00 Mil. It means Cyclacel Pharmaceuticals spent $0.00 Mil on purchasing business.
4. Sale Of Business:
Sale of business indicates the amount gained from selling business.
Cyclacel Pharmaceuticals's sale of business for the three months ended in Dec. 2023 was $0.00 Mil. It means Cyclacel Pharmaceuticals gained $0.00 Mil from selling business.
5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.
Cyclacel Pharmaceuticals's purchase of investment for the three months ended in Dec. 2023 was $0.00 Mil. It means Cyclacel Pharmaceuticals spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.
6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.
Cyclacel Pharmaceuticals's sale of investment for the three months ended in Dec. 2023 was $0.00 Mil. It means Cyclacel Pharmaceuticals gained $0.00 Mil from selling investments.
7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.
Cyclacel Pharmaceuticals's net Intangibles purchase and sale for the three months ended in Dec. 2023 was $0.00 Mil. It means Cyclacel Pharmaceuticals paid $0.00 Mil for net Intangibles purchase and sale.
8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.
Cyclacel Pharmaceuticals's cash from discontinued investing activities for the three months ended in Dec. 2023 was 0.00 Mil. It means Cyclacel Pharmaceuticals paid $0.00 Mil for discontinued investing activities.
9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.
Cyclacel Pharmaceuticals's cash from other investing activities for the three months ended in Dec. 2023 was $0.00 Mil. It means Cyclacel Pharmaceuticals paid $0.00 Mil for other investing activities.
Thank you for viewing the detailed overview of Cyclacel Pharmaceuticals's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.
Spiro Rombotis | director, officer: President & C.E.O. | C/O CYCLACEL PHARMACEUTICALS, INC., 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS NJ 07922 |
Paul Mcbarron | director, officer: E.V.P., Finance & C.O.O. | C/O CYCLACEL PHARMACEUTICALS, INC., 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS NJ 07922 |
Kenneth M. Ferguson | director | 2125 1ST AVENUE #2902, SEATTLE WA 98121-2121 |
Sam L Barker | director | 51 AUNT MOLLY ROAD, HOPEWELL NJ 08525 |
Brian Schwartz | director | C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803 |
Karin L Walker | director | C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Mark Kirschbaum | officer: Chief Medical Officer | 66 WEST 38TH STREET, APT. 19D, NEW YORK NY 10018 |
Robert J. Spiegel | director | C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025 |
Eastern Capital Ltd | 10 percent owner | 10 MARKET STREET, #773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006 |
Kevin C Tang | 10 percent owner | 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121 |
Tang Capital Partners Lp | 10 percent owner | 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121 |
Tang Capital Management Llc | 10 percent owner | 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121 |
Portfolio Services Ltd. | 10 percent owner | 10 MARKET STREET, # 773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006 |
Kenneth Bryan Dart | 10 percent owner | P. O. BOX 31300, GRAND CAYMAN E9 KY1-1206 |
Lloyd Sems | director | C/O SEMS CAPITAL, 7 DEY STREET, SUITE 1101, NEW YORK NY 10017 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 06-30-2022
By PurpleRose PurpleRose • 08-03-2022
By Value_Insider Value_Insider • 10-26-2022
By PurpleRose PurpleRose • 07-12-2022
By Value_Insider Value_Insider • 11-09-2022
By PurpleRose PurpleRose • 07-10-2022
By GuruFocusNews GuruFocusNews • 06-20-2022
By sperokesalga sperokesalga • 05-04-2023
By Marketwired • 11-07-2023
By Stock market mentor Stock market mentor • 01-05-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.